Regeneron Pharmaceuticals has made two major announcements this week. First, the company has agreed to a new deal with the White House to lower the prices of some of its medications. This agreement also protects Regeneron from certain extra taxes on imported drugs that were imposed by the previous administration. In return, Regeneron will reduce the price of its cholesterol medication, Praluent, by 58%. The price drop will lower the cost from $537 to $225 per month, but only if patients buy the drug through a special government website called TrumpRx.gov. Second, Regeneron has also agreed to charge ‘Most Favored Nation’ prices for all its future medicines. This means that any new drugs Regeneron releases will be priced in line with what other countries pay for similar treatments. One of these new drugs is Otarmeni, a gene therapy for a rare type of genetic hearing loss. The U.S. Food and Drug Administration (FDA) recently approved Otarmeni after a study showed that 80% of patients with this condition experienced hearing improvements after 24 weeks. This condition is very rare, affecting only 20 to 50 newborns in the U.S. each year. Regeneron has committed to providing Otarmeni for free to eligible American patients. In addition to these price reductions, Regeneron has promised to invest $27 billion in U.S. research and manufacturing by 2029. This investment will more than double the company’s production capacity in the United States. Regeneron is the 17th major pharmaceutical company to strike such a deal with the White House, as the government aims to make drugs more affordable and accessible. This effort comes as the U.S. has long struggled with high drug prices compared to other countries. The Trump administration has been working with drugmakers to reduce prices and encourage more manufacturing in the U.S. For example, the government has also introduced programs to lower the cost of weight loss medications like Zepbound and Wegovy to $50 per month for Medicare and Medicaid patients. However, a recent pilot program for these medications was paused due to pushback from insurance companies. Regeneron’s recent commitments are part of broader efforts to address drug pricing and improve access to life-saving treatments in America.